This study is in progress, not accepting new patients

RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa

a study on Retinitis Pigmentosa

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Jacque Duncan
Headshot of Jacque Duncan
Jacque Duncan

Description

Summary

Currently enrolling a total of 12 patients for Phase 2a of the study: 6 patients must have VA of no-better-than hand motion in the study eye, and 6 patients must have VA in the study eye to range from no-worse-than count fingers to 20/200 vision.

Official Title

Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)

Keywords

Advanced Retinitis Pigmentosa, gene therapy, optogenetics, channelrhodopsin, retina, retinitis pigmentosa, Retinitis, RST-001

Eligibility

You can join if…

Open to people ages 18 years and up

Participants must meet all of the following criteria.

  1. Age >= 18 years
  2. Signed and dated written informed consent obtained from the patient.
  3. Ability to comply with testing and all protocol tests.

You CAN'T join if...

Any one of the following will exclude patients from being enrolled into the study:

  1. Unable or unwilling to meet requirements of the study;
  2. Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months

Locations

  • UCSF- Dept. of Ophthalmology
    San Francisco California 94143 United States
  • Retina Foundation of the Southwest
    Dallas Texas 75231 United States
  • Cincinnati Eye Institute
    Cincinnati Ohio 45242 United States
  • Duke Eye Center
    Durham North Carolina 27710 United States

Lead Scientist at UCSF

  • Jacque Duncan
    Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.
ID
NCT02556736
Phase
Phase 1/2 Retinitis Pigmentosa Research Study
Study Type
Interventional
Participants
About 14 people participating
Last Updated